The pharmacokinetics of 400 mg norfloxacin administered orally were studied in 19 patients both during the acute phase of bacterial gastroenteritis and during convalescence, after normalization of bowel movements. The peak serum concentrations, total area under the serum concentration curve, rate of elimination and serum half-life in the beta-phase were all similar during the acute phase of the disease as well as after normalization of the intestinal function. The only difference was that the time to peak concentrations was longer (p less than 0.01) during the acute phase of the disease. That finding suggests that the faster intraintestinal transport of the drug during the acute stage of the disease leads to a reduced efficiency of early absorption. However, since the bioavailability was not affected, norfloxacin is obviously absorbed at a lower intestinal level and no dose adjustment should be necessary in patients with diarrhoea.

Download full-text PDF

Source

Publication Analysis

Top Keywords

acute phase
12
phase disease
8
consequences diarrhoeal
4
disease
4
diarrhoeal disease
4
disease pharmacokinetics
4
pharmacokinetics norfloxacin
4
norfloxacin pharmacokinetics
4
pharmacokinetics 400
4
400 norfloxacin
4

Similar Publications

Characteristics of In Vivo Lesion Formation With a Temperature-Controlled Diamond-Tip Radiofrequency Ablation Catheter in the Ventricle: A Preclinical Model.

Circ Arrhythm Electrophysiol

January 2025

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, MN (T.H., M.E.R., O.Y., G.N.K., N.O., T.K., L.N., D.L.P., K.C.S.).

Background: Power-controlled radiofrequency ablation with irrigated-tip catheters has been the norm for ventricular ablation for almost 2 decades. New catheter technology has recently integrated more accurate tissue temperature sensing enabling temperature-controlled irrigated ablation. We aimed to investigate the in vivo ablation parameters and lesion formation characteristics in ventricular myocardium using a novel temperature-controlled radiofrequency catheter.

View Article and Find Full Text PDF

Objective: This study investigated the effects of early treatment and pathophysiology on eosinophilic granulomatosis with polyangiitis neuropathy (EGPA-N).

Methods: Twenty-six consecutive patients with EGPA-N were diagnosed and treated within a day of admission and underwent clinical analysis. Peripheral nerve recovery rates were evaluated after early treatment by identifying the damaged peripheral nerve through detailed neurological findings.

View Article and Find Full Text PDF

Traditional herbal medicine for Guillain-Barré syndrome: A systematic review and meta-analysis.

Heliyon

January 2025

Stroke and Neurological Disorders Center, Kyung Hee University College of Korean Medicine, Kyung Hee University Hospital at Gangdong, Seoul, Republic of Korea.

Background: Guillain-Barré syndrome (GBS) is a rapid-onset disease caused by the immune system damaging the peripheral nervous system. Since most standardized treatments for GBS focus on acute phase treatment, there are limitations to the rehabilitation and management of general conditions. In East Asian countries, herbal medicine has been used to treat GBS and aid rehabilitation.

View Article and Find Full Text PDF

Objectives: Traumatic brain injury (TBI) is a significant cause of mortality and disability worldwide. TBI has been associated with factors such as oxidative stress, neuroinflammation, and apoptosis, which are believed to be mediated by the N-methyl-D-aspartate (NMDA)-type glutamate receptor. Two NMDA receptor antagonists, ketamine and memantine, have shown potential in mitigating the pathophysiological effects of TBI.

View Article and Find Full Text PDF

Background: Malnutrition is a significant challenge in stroke patients, affecting both rehabilitation and independence. This study aims to evaluate whether early L-carnitine supplementation can effectively improve anthropometric parameters and malnutrition status in acute-phase ischemic stroke patients to mitigate the catabolic state.

Methods: Eighty-two first-ever ischemic stroke patients were randomly assigned to either the L-carnitine group (1000 mg three times/day for seven consecutive days) or the matching placebo group.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!